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Amyotrophic lateral sclerosis is a relentless and devastating adult-onset neurodegenerative disease with no known cure. In mice
with amyotrophic lateral sclerosis, CD4
+ T lymphocytes and wild-type microglia potentiate protective inﬂammatory responses
and play a principal role in disease pathoprogression. Using this model, we demonstrate that endogenous T lymphocytes,
and more speciﬁcally regulatory T lymphocytes, are increased at early slowly progressing stages, augmenting interleukin-4
expression and protective M2 microglia, and are decreased when the disease rapidly accelerates, possibly through the loss of
FoxP3 expression in the regulatory T lymphocytes. Without ex vivo activation, the passive transfer of wild-type CD4
+ T
lymphocytes into amyotrophic lateral sclerosis mice lacking functional T lymphocytes lengthened disease duration and pro-
longed survival. The passive transfer of endogenous regulatory T lymphocytes from early disease stage mutant Cu
2+/Zn
2+
superoxide dismutase mice into these amyotrophic lateral sclerosis mice, again without ex vivo activation, were substantially
more immunotherapeutic sustaining interleukin-4 levels and M2 microglia, and resulting in lengthened disease duration and
prolonged survival; the stable disease phase was extended by 88% using mutant Cu
2+/Zn
2+ superoxide dismutase regulatory
T lymphocytes. A potential mechanism for this enhanced life expectancy may be mediated by the augmented secretion of
interleukin-4 from mutant Cu
2+/Zn
2+ superoxide dismutase regulatory T lymphocytes that directly suppressed the toxic proper-
ties of microglia; ﬂow cytometric analyses determined that CD4
+/CD25
+/FoxP3
+ T lymphocytes co-expressed interleukin-4 in
the same cell. These observations were extended into the amyotrophic lateral sclerosis patient population where patients with
more rapidly progressing disease had decreased numbers of regulatory T lymphocytes; the numbers of regulatory T lymphocytes
were inversely correlated with disease progression rates. These data suggest a cellular mechanism whereby endogenous regu-
latory T lymphocytes are immunocompetent and actively contribute to neuroprotection through their interactions with microglia.
Furthermore, these data suggest that immunotherapeutic interventions must begin early in the pathogenic process since immune
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increasing the levels of regulatory T lymphocytes in patients with amyotrophic lateral sclerosis at early stages in the
disease process may be of therapeutic value, and slow the rate of disease progression and stabilize patients for longer periods
of time.
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Introduction
Neuroinﬂammation is a prominent pathological feature in amyo-
trophic lateral sclerosis (ALS), a rapidly progressive disorder that
selectively destroys motoneurons resulting in death, and is
characterized by inﬁltrating lymphocytes, possibly related to the
increased chemokine (C–C motif) ligand 2 (CCL2) levels, and the
morphological activation of microglia (Engelhardt et al., 1993;
Alexianu et al., 2001; McGeer and McGeer, 2002; Henkel
et al., 2004, 2006, 2009; Turner et al., 2004; Zhang et al.,
2005, 2006; Boille ´e et al., 2006b; Appel et al., 2010). The
controversial role of T lymphocytes in ALS was resolved by our
demonstration that their presence in mutant Cu
2+/Zn
2+ super-
oxide dismutase (mSOD1) ALS mice plays an endogenous neuro-
protective function by augmenting the protective potentials of
microglia and attenuating their toxic responses (Beers et al.,
2008). Another study using mSOD1 mice bred with different
T lymphocyte-deﬁcient mice reached the similar conclusion that
T lymphocytes mediate a beneﬁcial inﬂammatory response; in
both studies, T lymphocyte deﬁciency led to the attenuation of
microglial protective responses and survival (Beers et al., 2008;
Chiu et al., 2008). Banerjee et al. (2008) also concluded that
the passive transfer of ex vivo activated CD4
+ T lymphocytes
into mSOD1 mice improved neurological function and life expect-
ancy. More recently, a T lymphocyte co-stimulatory pathway was
demonstrated to be upregulated in the blood of patients with ALS;
modulating this co-stimulatory pathway in ALS mice delayed dis-
ease onset and reduced toxic microglial inﬂammatory responses
(Lincecum et al., 2010).
The suppressive effects of CD4
+CD25
+FoxP3
+ regulatory T
lymphocytes (Tregs) on the adaptive and innate immune systems
have been documented (Sakaguchi et al., 2005, 2008; Tiemessen
et al., 2007). The passive transfer of ex vivo activated Tregs
was shown to suppress toxic microglial responses, upregulate
glial-derived neurotrophic factor and transforming growth
factor-b, and protected neurons in a model of Parkinson’s disease
(Reynolds et al., 2007, 2010). Treg-mediated suppression involves
multi-cellular clusters consisting of responder T lymphocytes,
antigen-presenting cells and membrane-bound and/or soluble
inhibitory molecules. Tregs suppress T lymphocyte proliferation,
downregulate pro-inﬂammatory cytokine production [interferon-g
(IFN-g) and tumour necrosis factor-] and directly inhibit interleu-
kin (IL)-2 messenger RNA transcription. Tregs secrete
anti-inﬂammatory cytokines (IL-4, IL-10 and IL-13) and neuro-
trophic factors, transform a pro-inﬂammatory Th1 response to
an anti-inﬂammatory Th2 mediated response and attenuate toxic
microglial responses; Tregs have been shown to directly differen-
tiate macrophages towards an alternatively activated (M2) state
(Avidan et al., 2004; Reynolds et al., 2007; Tiemessen et al.,
2007).
There was also controversy as to whether the proliferation and
activation of microglia in ALS promoted survival or exacerbated
neuronal death (Moisse and Strong, 2006). We and others
demonstrated that wild-type microglia or microglia expressing
less mSOD1 promoted neuroprotection and extended survival of
mSOD1 mice (Beers et al., 2006; Boille ´e et al., 2006b). In vitro
studies utilizing primary microglia/motoneuron co-cultures pro-
vided evidence that wild-type microglia were less neurotoxic
than mSOD1 microglia due to their enhanced release of neuro-
trophic factors and attenuated release of free radicals and pro-
inﬂammatory cytokines (Weydt et al., 2004; Beers et al., 2006;
Xiao et al., 2007). In microglia/motoneuron co-cultures, IL-4 pro-
moted motoneuron survival by suppressing classically activated
(M1) microglial activation, inducing an M2 protective phenotype,
reducing the release of the reactive oxygen species and enhancing
insulin-like growth factor-1 secretion (Zhao et al., 2006). Marden
et al. (2007) determined that dysregulated redox stress in ALS
mice caused by nicotinamide adenine dinucleotide phosphate oxi-
dase subunits Nox1 and Nox2, expressed in microglia, signiﬁcantly
inﬂuenced the progression of motoneuron disease caused by
mSOD1 expression; deletion of either Nox gene signiﬁcantly
slowed disease progression and improved survival. Therefore, T
lymphocytes and microglia, through their distinctive temporal
and spatial contributions, can have both neuroprotective and cyto-
toxic functions depending on their different phenotypic activation
states and the physiological conditions they encounter (Schwartz
and Shechter, 2010).
To pursue the role of T lymphocytes in the ALS pathogenic
process, and to determine the cellular mechanisms whereby dis-
tinct subpopulations of T lymphocytes and their interactions with
microglia enhance life expectancy in ALS, we demonstrate that
increased numbers of endogenous Tregs and M2 microglia were
associated with the stable phase of disease progression, whereas
Th1 lymphocytes and M1 microglia predominate during the rap-
idly progressing phase, suggesting a shift from protection to tox-
icity. Without ex vivo activation, the passive transfer of mSOD1
Tregs into ALS mice lacking functional T lymphocytes extended
the stable phase of disease progression and prolonged survival.
More importantly, decreased numbers of Tregs in the blood of
ALS patients with ALS correlated with faster progressing disease.
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Mice
mSOD1
G93A and recombination activating gene-2 (RAG2) knockout
mice, both on a C57Bl/6 genetic background, were bred and main-
tained in the Methodist Research Institute’s animal facility. All animals
were housed in microisolator cages with access to food and water ad
libitum, and all animals were speciﬁc pathogen free; sentinel mice
were tested quarterly. All experimental procedures involving animals
were approved by the Methodist Research Institute’s Institutional
Animal Care and Use Committee in compliance with National
Institutes of Health guidelines. Disease symptoms and course were
assessed using the Beers, Appel, Simpson, and Henkel (BASH) scoring
system (Beers et al., 2006, 2008). Speciﬁc cytokines/chemokines/
neurotrophic factor messenger RNA levels were assessed at disease
onset (11 weeks), the stable disease phase (14 and 16 weeks), the
point at which disease progression rapidly accelerates (18 weeks), the
rapidly progressing phase (20 weeks), and end stage disease;
age-matched wild-type mice served as controls.
Polymerase chain reaction screening
for mSOD1 and RAG2 mutations
Transgenic mSOD1
G93A animals were identiﬁed and copy number ver-
iﬁed by quantitative polymerase chain reaction as previously described
(Beers et al., 2008). The presence or absence of the RAG2 gene was
determined by polymerase chain reaction as previously described
(Beers et al., 2008). The polymerase chain reaction products were
resolved by 1.0% agarose/ethidium bromide gel electrophoresis and
photographed under UV illumination. The mSOD1 transgenic mice
were on the C57Bl/6 background, all from Jackson Laboratories.
Flow cytometry
Blood, cell suspensions from spleen and lymph nodes were isolated
from lethally anaesthetized mSOD1 and age-matched wild-type mice
at 11, 14, 16, 18 and 20 weeks of age, and at end stage disease, and
sent for ﬂow cytometric analyses (The Methodist Hospital Research
Institute’s Core Flow Cytometry Laboratory). The panel of antibodies
(BD Biosciences) used to evaluate the leucocytes from mice included
CD3, CD4, CD8, CD25, FoxP3 and IL-4. Human blood samples were
obtained in compliance with an approved Methodist Research Institute
Institutional Review Board. Human blood samples were evaluated
using CD3, CD4, CD8, CD25 and FoxP3 antibodies (BD
Biosciences). Data collection was performed on a LSRII ﬂow cytometer
(BD Biosciences) and analysed with FACSDiva (BD Biosciences) and
FlowJo (Tree Star) software.
T lymphocyte isolation and passive
transfers
T lymphocytes were isolated from the blood, spleen and lymph
nodes (axillary, inguinal and superﬁcial cervical) using a cell strainer,
pre-ﬁlter and CD4
+ T lymphocytes and CD4
+/CD25
+ Tregs were
separated using the Miltenyi MACS magnetic columns [CD4
+T
lymphocytes (130-095-248), CD4
+CD25
+ and CD4+CD25  T
lymphocytes (130-091-041)] according to the manufacturer’s instruc-
tions. Purity was conﬁrmed by ﬂow cytometry. Isolated T lymphocyte
subpopulations were passively transferred into 70-day-old
mSOD1/RAG2
 /  mice via tail vein injections and repeated every
28 days. Total leucocytes (2   10
8) were isolated from the spleens
and lymph nodes of 14-week-old mSOD1 mice. From the total leuco-
cytes, 2   10
7 were CD4
+ T lymphocytes, and of these cells, 2–
3   10
6 were CD4
+/C25
+ Tregs. Thus, approximately 1–1.5% of
the total leucocytes population was Tregs or 10–15% from the
CD4
+ T lymphocyte population; there were consistently 2–3 times
more mSOD1 Tregs isolated from mSOD1 mice than similarly isolated
wild-type Tregs from age- and genetic background-matched wild-type
mice. Analysis of the isolated CD4
+/C25
+ Tregs by ﬂow cytometry
determined that this population of cells was 90–95% CD4
+/C25
+
T lymphocytes; thus, this population contained few CD4
+/CD25
 
effector T lymphocytes (Teffs). Furthermore, ﬂow cytometry revealed
that 480% of the mSOD1 CD4
+/C25
+ T lymphocytes were FoxP3
+.
Ten-week-old mSOD1/RAG2
 /  mice were passively transferred with
2   10
7 wild-type or mSOD1 CD4
+ T lymphocytes, or with 2–3   10
6
mSOD1 Tregs, from 14-week-old mSOD1 or age-matched
wild-type mice.
Quantitative reverse transcriptase
polymerase chain reaction
RNA was isolated from homogenized frozen spinal cord tissue or
cell cultures using TRIzol (Gibco) and puriﬁed with RNeasy
(Qiagen) according to the manufacturer’s recommendations. The
concentrations were determined spectrophotometrically (Beckman
DU-64). Quantitative reverse transcriptase polymerase chain reaction
was performed on 10ng of messenger RNA (or 2ng of culture mes-
senger RNA) as previously described (Henkel et al., 2006; Beers et al.,
2008). Primer efﬁciency was assessed by analysing a dilution series of
messenger RNA. The relative expression level of each messenger RNA
was calculated using the
Ct method normalizing to b-actin and
relative to the control samples. The presence of one product of the
correct size was veriﬁed by gel electrophoresis and melting curve
analyses.
Cell culture
Primary adult microglia were prepared from spinal cord tissues of
18-week-old mSOD1
G93A mice as well as wild-type mice by modiﬁca-
tion of a non-enzymatic procedure (Aloisi et al., 2000; Frank et al.,
2006). Brieﬂy, mice were lethally anaesthetized and perfused intra-
cardially with 40–50ml of ice-cold glucose–potassium–sodium (GKN)
buffer [8g/l NaCl, 0.4g/l KCl, 3.56g/l Na2HPO4 12H2O, 0.78g/l
NaH2PO4 2H2O and 2g/l D(+)-glucose, pH 7.4]. Spinal cord tissues
were mechanically dissociated by passing through a 70mm cell strainer
using a 10ml syringe plunger, and then strained through a 40-mm
ﬁlter. After centrifugation at 350g for 10min at 4 C, dissociated
tissue was resuspended in 2ml of 70% isotonic Percoll and overlaid
with 3ml of 35% Percoll and 2ml of phosphate-buffered saline
following a 30-min centrifugation at 800g,2 0  C. Microglia were
obtained from the 35%:70% interface, washed and resuspended
in Roswell Park Memorial Institute (RPMI) medium supplemented
with 10% foetal bovine serum, 25mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, 1mM sodium pyruvate,  1 non-
essential amino acids, 55mM 2-mercaptoethanol, 100U/ml penicillin
and 100mg/ml streptomycin.
Tregs and Teffs were obtained from lymph nodes (superﬁcial cer-
vical, axillary, inguinal lymph nodes) and spleen of 14-week-old
mSOD1
G93A mice as well as wild-type littermates. Tregs and Teffs
were isolated using mouse regulatory T-cell isolation kits (Miltenyi
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resulting T-cell populations was conﬁrmed to be 495% by ﬂow
cytometry.
Primary adult microglia (1   10
4) were co-cultured with Tregs or
Teffs (1   10
4) in 96-well U-bottom plates in complete Roswell Park
Memorial Institute (RPMI) medium with 0.5mg/ml anti-CD3 antibody
(eBioscience) and 100 U/ml IL-2 (BD Biosciences). In the inhibitory
experiments, blocking antibodies of IL-4 (150ng/ml, R&D Systems)
or IL-10 (10mg/ml, eBioscience) were added to the co-cultures after
plating. Two days later, cells were lysed to extract RNA with RNeasy
Micro kit (Qiagen) to detect NOX2 and IL-10. Supernatant was
collected for detecting IL-4 protein using an enzyme-linked immuno-
sorbent assay kit from eBioscience.
To assay whether mSOD1 Tregs can functionally suppress mSOD1
microglia, microglia were isolated from the spinal cords of 18-week-old
untreated mSOD1 mice that were entering the rapidly progressing
disease phase; microglia at this time point had reduced expression of
Ym1 and increased expression of NOX2 messenger RNA. The mSOD1
Tregs were isolated from 100-day-old mSOD1 mice because these
animals are on the stable disease phase and have increased numbers
of functional Tregs. Thus, the assay determined whether Tregs isolated
from stable phase mSOD1 mice are able to suppress the neurotoxic
microglia.
Immunohistochemistry
The mice were lethally anaesthetized and perfused with phosphate-
buffered saline (pH 7.4) followed by 3% neutral paraformaldehyde.
Sections (30mm) were cut from the spinal cord and washed three
times in phosphate-buffered saline. The sections were blocked for en-
dogenous peroxidase activity (0.3% H2O2 in distilled water, 30min).
The sections were pretreated with normal serum for 1h at room
temperature to block the non-speciﬁc IgG binding sites. The primary
antibodies were diluted in phosphate-buffered saline containing
normal serum and incubated overnight at 4 C. As a negative control,
the primary antibodies were omitted during the reaction. After rinsing
in phosphate-buffered saline, the sections were incubated with a bio-
tinylated secondary IgG for 2h at room temperature. The immunos-
tained sections were examined using a Zeiss Imager-Z1m microscope
equipped with a Zeiss AxioCam MRc5 colour camera, a Zeiss AxioCam
MRm black and white camera and a Zeiss digital image analysis system
(Karl Zeiss).
Patients
After receiving written informed consent, peripheral whole blood was
drawn from 54 patients diagnosed with deﬁnite or probable sporadic
ALS according to revised El Escorial criteria of the World Federation of
Neurology (Brooks, 1994). The cohort consisted of 31 males and
23 females, ranging in age from 35 to 74 years (mean age of
59   10 SD), with 28% of the patients having bulbar region disease
onset, whereas the remaining 72% had limb onset. The patients were
evaluated at the MDA/ALS Clinic at the Methodist Neurological
Institute from 2000 to 2010 using the Appel ALS functional status
score (Haverkamp et al., 1995). Based on the Appel ALS score, the
ALS patients were separated into slowly (a disease progression rate of
51.5 Appel ALS points/month) versus rapidly (a disease progression
rate of 51.5 Appel ALS points/month) progressing patients.
Additional peripheral blood samples were donated by 33 healthy con-
trol volunteers (13 males and 20 females; ages ranged from 31 to 73
years with a mean age of 54   11 SD) after giving written informed
consent. The control volunteers did not have histories of infectious
diseases or other disorders.
Statistical analyses
Data were analysed by two-tailed Student’s t-test on Excel software.
Data are expressed as mean   SE; P50.05 was considered statistically
signiﬁcant. Differences in onset and survival times were computed
using Kaplan–Meier survival statistics (log rank sum test, Number
Cruncher Statistical Systems). Disease progression and the in vitro
studies were analysed by a one-way ANOVA with repeated measures
(SigmaStat). Differences between groups were analysed using a
two-way ANOVA (SigmaStat).
Results
Regulatory T lymphocytes are
increased in mSOD1mice
Since CD4
+ T lymphocytes provide neuroprotection by modulat-
ing the trophic/cytotoxic balance of glia (Beers et al., 2008; Chiu
et al., 2008), and since they play a prominent role in slowing the
rate of progression in ALS mice, speciﬁc T lymphocyte populations
in blood, spleens and lymph nodes from the C57Bl/6 strain of
mSOD1
G93A ALS mice were temporally analysed by ﬂow cytome-
try and compared with their wild-type littermates. Analyses were
performed at disease onset (11 weeks), the stable disease phase
(14 and 16 weeks), the point at which disease progression begins
to rapidly accelerate (18 weeks), the rapidly progressing phase (20
weeks) and end stage disease ( 23 weeks; Fig. 1A and
Supplementary Fig. 1A). Total leucocytes counts were initially
elevated in blood, spleen and lymph nodes of mSOD1 mice but
decreased as disease progressed (Supplementary Fig. 1B–D).
CD3
+ and CD4
+ T lymphocytes were increased in the blood of
mSOD1 mice at 16 weeks through end stage disease compared
with their wild-type littermates (Supplementary Fig. 1E and F).
CD8
+ T lymphocytes were only increased in the blood of end
stage mSOD1 mice (Supplementary Fig. 1G). In spleens, CD3
+,
CD4
+ and CD8
+ T lymphocytes increased in mSOD1 mice at end
stage disease (Supplementary Fig. 1H–J). In lymph nodes, CD3
+
and CD4
+ T lymphocytes were also increased at 18 weeks in
mSOD1, but CD8
+ T lymphocytes were only increased at 18
weeks (Supplementary Fig. 1K–M).
CD4
+CD25
+ and CD25
+FoxP3
+ Tregs were increased in the
blood of mSOD1 mice at every time point analysed, peaking at
16 weeks (Fig. 1B and C). FoxP3 ﬂuorescent intensity, an assess-
ment of the level of FoxP3 expression in lymphocytes, was
increased in blood CD25
+FoxP3
+ Tregs at 11, 14 and 16
weeks, but was at wild-type levels at 18 weeks and thereafter
(Fig. 1D); expression of FoxP3 at low levels induces a limited
Tregs phenotype without suppressive functions, which is only
gained once FoxP3 is highly expressed (Sakaguchi et al., 2010).
In spleens of mSOD1 mice, CD4
+CD25
+ Tregs were increased at
11 weeks, and then decreased at 16 weeks, but gradually
recovered thereafter (Supplementary Fig. 1N). FoxP3 ﬂuorescent
intensity was not different in cells isolated from spleens (data not
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+CD25
+ and CD25
+FoxP3
+ Tregs
were increased between 16 and 20 weeks; CD25
+FoxP3
+ Tregs
were only increased in the spleens of mSOD1 mice at end stage
disease (Fig. 1E and F; Supplementary Fig. 1O). As in blood, the
ﬂuorescent intensity of CD25
+ Tregs was increased in ALS mice
lymph nodes at 11, 14 and 16 weeks, but was at wild-type levels
at 18 weeks (Fig. 1G); in both blood and lymph nodes, FoxP3
intensity levels began to diminish at 16 weeks. Thus, although
the total leucocytes counts were waning, or possibly inhibited,
as disease progression accelerated, speciﬁc subpopulations of
lymphocytes changed, suggesting that a single time point does
not adequately reﬂect an animal’s immune status.
Figure 1 Flow cytometric analyses showed the temporal changes of T lymphocyte sub-populations in blood and lymph nodes of mSOD1
mice. (A) Graph of the disease progression curve and time points (arrows) when ﬂow cytometry and quantitative reverse transcriptase
polymerase chain reaction assays were performed on wild-type and mSOD1 mice. Each time point represents the mean of n = 3 mSOD1
and n = 3 wild-type (WT) littermate mice. (B) CD4
+CD25
+ cells were increased in the blood of mSOD1 mice at each time point examined
except at end stage disease. (C) Including end stage disease, CD25
+FoxP3
+ cells were increased in the blood of mSOD1 mice at each time
point examined. (D) The FoxP3 ﬂuorescence/cell intensity in the blood suggests that the Tregs have a suppressive function at 11 through
16 weeks, but these suppressive capabilities are possibly lost at 18 weeks through end stage disease. (E) In lymph nodes, CD4
+CD25
+
cells were increased between 16 and 20 weeks, but returned to wild-type levels at end stage disease. (F) CD25
+FoxP3
+ cells followed a
similar pattern as CD4
+CD25
+ cells in lymph nodes compared with wild-type mice. (G) As occurred in the blood, the FoxP3 ﬂuorescence/
cell intensity in the lymph nodes suggests that the Tregs have a suppressive function between 11 and 16 weeks, but possibly lose this
capability at 18 weeks through to end stage disease. ES = end stage; *P40.05, mSOD1 compared with wild-type mice; **P40.01,
mSOD1 compared with wild-type mice; and # P40.05, 16 week compared with 18 week mSOD1 mice.
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and their prototypic cytokines are
temporally and differentially expressed
in spinal cords of mSOD1 mice during
disease progression
Because FoxP3
+ cells were detected in the periphery of mSOD1
mice during the stable disease phase (Fig. 1A), and to determine if
these cells are possibly inﬁltrating the CNS, spinal cord messenger
RNA from mSOD1 mice was assayed by quantitative reverse
transcriptase polymerase chain reaction for the presence of
FoxP3. FoxP3 messenger RNA was increased in mSOD1 mice at
11 through to 16 weeks, prior to and during the stable disease
phase, compared with their wild-type littermates (Fig. 2A).
However, as disease progression began to accelerate and disease
burden increased, FoxP3 messenger RNA decreased. Therefore,
the temporal expression of FoxP3 messenger RNA levels in the
lumbar spinal cords of mSOD1 mice reﬂected the numbers of
Tregs, and their ﬂuorescent intensities, in the blood and lymph
nodes over the same time points.
Since the message for FoxP3 was elevated during the stable
phase of disease progression, messenger RNAs for speciﬁc
anti-inﬂammatory cytokines were assayed for whether they were
increased during the stable phase of disease progression. Both IL-4
and IL-10 messenger RNAs were increased in the spinal cords of
mSOD1 mice during the stable disease phase (Fig. 2B and C).
Although the messenger RNA for IL-4 remained elevated until
end stage disease, IL-10 returned to wild-type levels at
20 weeks and was suppressed below wild-type levels at end
stage disease. In addition, to determine whether messenger
RNAs for these prototypic cytokines were increased due to the
inﬁltration of Th2 lymphocytes, the lumbar spinal cords of these
animals were assessed for levels of Gata-3 messenger RNA, a
master transcription factor preferentially expressed by Th2
lymphocytes (Zhu and Paul, 2010); Gata-3 has also been found
to be expressed in neurons, astrocytes and microglia (Wallach
et al., 2009). Gata-3 was not increased in the lumbar region of
mSOD1 mice spinal cords compared with the lumbar region of
wild-type mice; Gata-3 expression was not elevated at any time
point examined (Fig. 2D). However, Gata-3 messenger RNA levels
were suppressed in the lumbar regions of mSOD1 mice beginning
at 18 weeks, and extended through end stage disease, compared
with the respective region in wild-type mice; of all of the quanti-
tative reverse transcriptase polymerase chain reaction studies per-
formed, only the Gata-3 result showed a suppression at 18 weeks
through end stage disease in ALS mice compared with wild-type
mice with the single exception of IL-10, which was below
wild-type levels at end stage disease.
One complement to the Gata-3/Th2 component of the immune
system is T-bet/Th1. T-bet, also known as T-box 21 (Tbx21), is a
master transcription factor preferentially expressed in Th1 lympho-
cytes (Zhu and Paul, 2010). To determine if Th1 lymphocytes are
inﬁltrating the lumbar spinal cords of ALS mice, their lumbar cords
were assessed for levels of T-bet messenger RNA. The message for
T-bet was increased in the lumbar spinal cords of mSOD1 mice at
14 and 16 weeks compared with the lumbar regions of wild-type
mice, and increased further at 18 weeks through end stage disease
(Fig. 2E). The messenger RNA for IFN-g, the prototypic
pro-inﬂammatory cytokine released by T-bet/Th1 lymphocytes,
was increased in mSOD1 mice at 18 and 20 weeks, and at end
stage disease (Fig. 2F). IL-12 messenger RNA, produced primarily
by activated inﬂammatory cells including microglia and dendritic
cells, which acts to differentiate naı ¨ve CD4
+ T lymphocytes into
IFN-g secreting Th1 cells, was increased beginning at 16 weeks
and remained elevated throughout the disease course
(Supplementary Fig. 2A). The message for IL-17, the pro-
inﬂammatory cytokine produced by Th17 cells, was not detected
in spinal cords of mSOD1 or wild-type mice at any time point
(data not shown).
Glia messenger RNAs are temporally
and differentially expressed in the
lumbar spinal cords of mSOD1
mice during disease progression
Since we previously demonstrated that morphological markers of
glial ‘activation’ do not accurately predict the functional markers
of ‘activation’, we assessed the levels of Ym1 messenger RNA as a
marker for M2 protective microglia in the lumbar spinal cords of
mSOD1 mice compared with age-matched wild-type mice (Beers
et al., 2008). Ym1 was increased at 11 weeks in mSOD1 mice,
peaked between 14 and 16 weeks, then decreased at 18 weeks
through end stage disease, but remained elevated compared with
wild-type mice (Fig. 3A). CD206, also known as the mannose
receptor, c type 1 or MRC1, was assayed as another marker for
M2 microglia (Colton et al., 2006; Tiemessen et al., 2007; Gordon
and Martinez, 2010). The message levels of CD206 reliably
mirrored that of Ym1 messenger RNA, but to a slightly lower
‘fold increase’ over the course of disease in mSOD1 mice;
CD206 peaked at 14 weeks with a 4-fold increase, whereas
Ym1, also peaking at 14 weeks, had a 25-fold increase in the
messenger RNA expression level at this time point (Fig. 3B).
Another marker of protective microglia, fractalkine receptor
(CX3CR1) messenger RNA, expressed on microglia, dendritic
cells and T lymphocyte subsets, and which has been shown to
protect motoneurons by suppressing microglial toxicity, mirrored
levels of Ym1 and CD206 (Fig. 3C) (Cardona et al., 2006).
Because CD4
+ T lymphocytes protect facial motoneurons, pos-
sibly through brain-derived neurotrophic factor, we temporally
assessed the levels of brain-derived neurotrophic factor messenger
RNA in the spinal cords of mSOD1 mice (Serpe et al., 2005).
Brain-derived neurotrophic factor was increased in the spinal
cords of mSOD1 mice at 14 and 16 weeks, but returned to
wild-type levels at 18 weeks (Supplementary Fig. 3A). In contrast,
the messenger RNA for glial-derived neurotrophic factor, another
neurotrophic factor, was increased at 11 weeks, peaked at 16
weeks, declined slightly until end stage disease, but remained
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tive cytokine transforming growth factor-b was increased in
mSOD1 mice beginning at 14 weeks and increased throughout
the disease course (Supplementary Fig. 3C).
We also determined if speciﬁc toxic M1 microglial factors
were elevated when disease progression accelerated (Fig. 1A).
NOX2, the subunit of nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase found in macrophages producing
superoxide anions (O
  
2 ), increased rapidly in mSOD1 mice
beginning at 14 weeks and was markedly elevated at end
stage disease (Fig. 3D). Similarly, the messenger RNA for IL-1b,
released by toxic M1 macrophages and microglia, was increased
Figure 2 Quantitative reverse transcriptase polymerase chain reaction analyses revealed the temporal and differential expression of
markers for subsets of T lymphocytes and their prototypic cytokines during disease progression. (A) FoxP3 messenger RNA, currently the
most reliable marker of Tregs, was increased in the spinal cords of mSOD1 mice at 11, 14 and 16 weeks of age, but was at wild-type levels
at 18 weeks through to end stage (ES) disease. (B) The messenger RNA for IL-4, the prototypic Th2 released cytokine that is also released
by Tregs, was ﬁrst increased during the stable disease phase, then abruptly dropped at the beginning of the rapidly progressing phase, but
was still elevated until end stage disease. (C) IL-10 messenger RNA, another Tregs and Th2 released cytokine, was increased during the
stable phase of disease; IL-10 abruptly decreased at the beginning of the rapidly progressing disease phase and continued to decline until
end stage disease. (D) The message for Gata-3, a master transcription factor expressed in Th2 lymphocytes, was suppressed at 18 weeks
through to end stage disease. (E) In contrast to Gata-3, T-bet messenger RNA, a master transcription factor expressed in Th1 lymphocytes,
was increased at 14 through to 18 weeks, and then increased further at 20 weeks and end stage disease. (F) The messenger RNA for
IFN-g, the prototypic pro-inﬂammatory cytokine released by Th1 cells, was increased at 18 and 20 weeks, and at end stage disease. n =3
mSOD1 and n = 3 wild-type littermate mice at each time point. *P40.05, mSOD1 compared with wild-type mice; **P40.01, mSOD1
compared with wild-type mice;
#P40.05, 11 week compared with 14 week mSOD1 mice;
##P40.01, 11 week compared with 14 week
mSOD1 mice;
&P40.01, 14 week compared with 16 week mSOD1 mice;
$P40.05, 16 week compared with 18 week mSOD1 mice;
$$P40.01, 16 week compared with 18 week mSOD1 mice;
+P40.05, 18 week compared with 20 week mSOD1 mice; and
++P40.01, 18 week compared with 20-week mSOD1 mice.
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(Fig. 3E). Tumour necrosis factor- messenger RNA, also released
by M1 microglia, was modestly increased between 16 and
20 weeks, and then spiked at end stage disease (Supplementary
Fig. 3D). The message for IL-6, although thought of as a
Th1 produced cytokine, but is predominantly produced by
activated astrocytes in the CNS, was elevated between 16 and
20 weeks, possibly decreasing the number of Tregs over
this same time period (Fig. 3F) (Van Wagoner and Benveniste,
1999).
Figure 3 Quantitative reverse transcriptase polymerase chain reaction analyses showed a differential expression of glial messenger RNAs
during disease progression in the spinal cords of mSOD1 mice. (A) Ym1 messenger RNA, a reliable marker of M2 macrophages/microglia,
was increased in spinal cords of mSOD1 mice at 11 through to 16 weeks of age, and remained elevated through to end stage (ES) disease
compared with wild-type mice. (B) CD206, another marker of M2 microglia, mirrored that of Ym1. (C) CX3CR1 (fractalkine receptor)
messenger RNA, expressed in microglia, dendritic cells and T lymphocyte subsets, and has been shown to protect motoneurons by
suppressing microglial toxicity, was increased in spinal cords of mSOD1 mice at 11 through to 16 weeks of age, and remained elevated
through to end stage disease compared with wild-type mice. (D) NOX2 messenger RNA, the prototypic subunit of nicotinamide adenine
dinucleotide phosphate oxidase found in macrophages/microglia producing O
  
2 , was increased at 14 and 16 weeks of age, and was
dramatically increased at 18 weeks (18-fold), the beginning of the rapidly progressing disease phase (Beers et al., 2008). Notice the scale
of the ordinate in this graph. (E) IL-1b messenger RNA expression pattern, released by microglia, was increased at 14 and 16 weeks of age
in spinal cords of mSOD1 mice compared with wild-type mice, and was increased further at 18 weeks, the beginning of the rapidly
progressing disease phase (Beers et al., 2008), through to end stage disease. (F) The messenger RNA level for IL-6, another Th1-induced
cytokine that completely inhibits the generation of FoxP3
+ Tregs and possibly key factor that transforms Tregs/Th2 and M2 responses into
Th1/M1 responses, was increased at 16 through to 20 weeks of age. n = 3 mSOD1 and n = 3 wild-type littermate mice at each time point.
*P40.05, mSOD1 compared with wild-type mice; **P40.01, mSOD1 compared with wild-type mice;
#P40.05, 11-week mSOD1
mice compared with 14-week mSOD1 mice;
##P40.01, 11-week mSOD1 mice compared with 14-week mSOD1 mice;
&P40.05,
14-week mSOD1 mice compared with 16-week mSOD1 mice;
$P40.01, 16-week mSOD1 mice compared with 18-week mSOD1 mice;
$$P40.01, 16-week mSOD1 mice compared with 18-week mSOD1 mice;
+P40.05, 18-week mSOD1 mice compared with 20-week
mSOD1 mice;
zP40.05, 20-week mSOD1 mice compared with end stage mSOD1 mice; and
zzP40.01, 20-week mSOD1 mice
compared with end stage mSOD1 mice.
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receptor 2, dendritic and phagocytic
macrophage phenotypic marker
messenger RNAs are also increased in
the lumbar spinal cords of mSOD1 mice
during the rapidly progressing disease
phase
Full T lymphocyte activation requires interaction between CD28
on the surface of T lymphocytes with CD80 or CD86 on
antigen-presenting cells. CD28 messenger RNA was increased at
11 and 14 weeks in mSOD1 mice, returned to wild-type levels
at 16 weeks and then increased again at 18 weeks through to end
stage disease (Supplementary Fig. 4A). CD80 expression levels
peaked at 14 weeks in mSOD1 mice, dropped slightly at 16
weeks, was at wild-type levels at 18 weeks, and then increased
again at 20 weeks and end stage disease (Supplementary Fig. 4B).
In contrast, CD86 increased after 18 weeks (Supplementary Fig. 4C).
CTLA-4 messenger RNA, a co-stimulatory molecule on the surface
of Tregs that also binds CD80 or CD86, was not detected in the
spinal cords of either mSOD1 or wild-type mice (data not shown).
The messenger RNA for CD11c, a dendritic cell marker, was
increased at 14 weeks and continued to increase at every other
time point assayed (Supplementary Fig. 4D). A possible pathway
to activate dendritic cells is through toll-like receptors. Compared
with their wild-type littermates, toll-like receptor-2 messenger
RNA levels mirrored the CD11c messenger RNA pattern
(Supplementary Fig. 4E). In addition, toll-like receptor-4 messen-
ger RNA levels were increased in mSOD1 mice (Supplementary
Fig. 4F). This suggests the presence of an infectious agent or
‘rogue protein’; possibly the release of misfolded mSOD1 from
motoneurons and astrocytes (Urushitani et al., 2006; Appel
et al., 2010; Zhao et al., 2010). CD68 messenger RNA levels, a
lysosomal-associated membrane protein found on phagocytic cells,
were increased in the spinal cords of mSOD1 mice at all time
points (Supplementary Fig. 4G). A possible chemokine responsible
for the recruitment of leucocytes to areas of CNS injury is chemo-
kine (C-C motif) ligand 2 (CCL2) and its temporal messenger RNA
expression pattern was similar to the CD68 messenger RNA
pattern (Supplementary Fig. 4H).
mSOD1 regulatory T lypmphocytes
augment neuroprotection and extend
the stable disease phase
To determine if endogenous mSOD1 CD4
+ T lymphocytes with
enhanced numbers of Tregs and without ex vivo activation are
capable of providing neuroprotection, mSOD1/RAG2
 /  mice
were passively transferred with CD4
+ T lymphocytes from stable
disease phase mSOD1 mice or age-matched wild-type mice and
compared with their mSOD1/RAG2
+/  littermates; all mice were
speciﬁc pathogen free and did not display clinical signs of other
illnesses such as graft versus host disease (Fig. 1A) (Banerjee et al.,
2008; Beers et al., 2008; Chiu et al., 2008). Disease progression
was unchanged between mSOD1/RAG2
 /  mice passively trans-
ferred with wild-type CD4
+ T lymphocytes and mSOD1/RAG2
+/
  littermates (Fig. 4A; Supplementary Fig. 5A) (Beers et al., 2008).
mSOD1/RAG2
 /  mice receiving wild-type CD4
+ T lymphocytes
had disease onset (data not shown), duration (time from onset
until death) and survival times similar to those of mSOD1/
RAG2
+/  mice; previous studies documented that mSOD1/
RAG2
+/  mice survive similarly to mSOD1 mice (Fig. 4B and C;
Supplementary Fig. 5B and C) (Beers et al., 2008).
Passively transferring mSOD1 CD4
+ T lymphocytes harvested
from mSOD1 donor mice during the stable disease phase with an
enhanced number of Tregs extended the stable disease phase of
recipient mSOD1/RAG2
 /  mice by 2 weeks compared with mice
receiving wild-type CD4
+ T lymphocytes (Fig. 4A). Stable phase
mSOD1 CD4
+ T lymphocytes prolonged duration and survival
times compared with mSOD1/RAG2
 /  mice transferred with
wild-type CD4
+ T lymphocytes (an 11 and 20% increase, respect-
ively) or mSOD1/RAG2
+/  mice (a 14 and 21% increase,
respectively); onset times among the three groups were not dif-
ferent (Fig. 4B and C; Supplementary Fig. 5B and C). As a control,
the transfer of mSOD1 CD4
+ T lymphocytes harvested from
rapidly progressing 20-week-old mSOD1 mice, lacking the
increased number of Tregs, into recipient mSOD1/RAG2
 / 
mice did not extend the stable phase; these mice had duration
and survival times similar to mSOD1/RAG2
 /  mice passively
transferred with wild-type CD4
+ T lymphocytes (data not shown).
To ensure that the mSOD1 Tregs in the mSOD1 CD4
+
T lymphocyte population were responsible for extending the
stable phase and prolonging survival, CD4
+CD25
+ Tregs were
isolated from the total population of stable phase mSOD1 CD4
+
T lymphocytes and transferred into recipient mSOD1/RAG2
 / 
mice without ex vivo expansion; there were consistently 2–3
times more mSOD1 Tregs isolated from mSOD1 mice than simi-
larly isolated wild-type Tregs from age- and genetic
background-matched wild-type mice. mSOD1 Tregs further
extended the stable disease phase by 1.5 weeks compared with
total mSOD1 CD4
+ T lymphocytes (Fig. 4A). The survival times
between mSOD1/RAG2
 /  mice receiving stable phase mSOD1
Tregs and mSOD1/RAG2
 /  mice receiving total stable phase
mSOD1 CD4
+ T lymphocytes were equivalent (Fig. 4B and C).
mSOD1 CD4
+/CD25
  Teffs were passively transferred into
mSOD1/RAG2
 /  mice. However, these mice quickly became
sick, without ALS-like signs of disease, and were sacriﬁced;
Tregs are critical for the prevention of autoimmunity and
maintenance of self-tolerance.
Since FoxP3, Gata-3 and T-bet messenger RNAs were differen-
tially expressed in mSOD1 mice during the stable phase, and since
the passive transfer of mSOD1 CD4
+ or CD4
+/CD25
+ T lympho-
cytes prolonged survival, their messenger RNA levels were
assessed in spinal cords of 20-week-old mSOD1/RAG2
 /  mice
passively transferred with wild-type CD4
+, mSOD1 CD4
+ or
mSOD1 CD4
+/CD25
+ T lymphocytes and compared with
age-matched wild-type and mSOD1 mice; mice receiving passive
transfers of T lymphocytes were sacriﬁced at 20 weeks of age
because this is the time point where untreated mSOD1 mice are
well into the rapidly progressing disease phase. The passive
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 /  mice. Total
mSOD1 CD4
+ T lymphocytes and CD4
+CD25
+ Tregs were harvested from mSOD1 mice during the stable disease phase (100–115 days
of age), and total wild-type CD4
+ T lymphocytes were isolated from 100- to 115-day-old wild-type (WT) mice. Neither the total mSOD1
CD4
+ T lymphocytes nor the total wild-type CD4
+ T lymphocytes were expanded ex vivo.( A) The stable disease phase in ALS mice,
represented by the plateau in the disease progression curve, was extended 2 weeks following the passive transfer of total mSOD1 CD4
+ T
lymphocytes (purple curve) into mSOD1/RAG2
 /  mice (n = 10) compared with mSOD1/RAG2
 /  mice receiving age-matched total
wild-type CD4
+ T lymphocytes (dark blue curve; n =6 ;P 5 0.001). The stable disease phase did not differ between mSOD1/RAG2
 / 
mice passively transferred with total wild-type CD4
+ T lymphocytes. The passive transfer of mSOD1 Tregs further extended the stable
disease phase by 1.5 weeks in mSOD1/RAG2
 /  mice (green curve; n = 6) compared with mSOD1/RAG2
 /  mice passively transferred
with total mSOD1 CD4
+ T lymphocytes (purple curve; P = 0.028). The passive transfer of mSOD1 Tregs extended the stable disease
phase by 100% compared with the passive transfer of wild-type CD4
+ T lymphocytes. mSOD1 Tregs extended the stable disease phase
by 8 weeks compared with untreated mSOD1/RAG2
 /  mice (red curve; n = 14). (B) The passive transfer of total mSOD1 CD4
+ T
lymphocytes (purple curve) or mSOD1 Tregs (green curve) into mSOD1/RAG2
 /  mice prolonged survival compared with mSOD1/
RAG2
 /  mice passively transferred with total wild-type CD4
+ T lymphocytes (dark blue curve; P 5 0.001 and P = 0.001, respectively).
Passive transfer of total mSOD1 CD4
+ T lymphocytes or mSOD1 Tregs into mSOD1/RAG2
 /  mice prolonged survival by 38 days (26%)
compared with untreated mSOD1/RAG2
 /  mice (red curve, P 5 0.001 and P 5 0.001, respectively). Passive transfer of total mSOD1
CD4
+ T lymphocytes into mSOD1/RAG2
 /  mice did not prolong survival compared with mSOD1/RAG2
 /  mice receiving mSOD1
Tregs. (C) Passive transfer of total mSOD1 CD4
+ T lymphocytes (purple bar) or mSOD1 Tregs (green bar) into mSOD1/RAG2
 /  mice
extended duration compared with mSOD1/RAG2
 /  mice passively transferred with total wild-type CD4
+ T lymphocytes (dark blue bar;
P = 0.003 and P = 0.018, respectively). Passive transfer of total mSOD1 CD4
+ T lymphocytes or mSOD1 Tregs into mSOD1/RAG2
 / 
mice extended duration by 36 days (50%) and 33 days (46%) compared with untreated mSOD1/RAG2
 /  mice (red bar; P 5 0.001 and
P 5 0.001, respectively). Because disease onset was not different among all groups, disease duration was not different between mSOD1/
RAG2
 /  mice passively transferred with total mSOD1 CD4
+ T lymphocytes and mSOD1/RAG2
 /  mice receiving mSOD1 Tregs.
(D) At 20 weeks of age, the passive transfer of mSOD1 CD4
+ (purple bar) or CD4
+/CD25
+ T lymphocytes (green bar) increased the
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(continued)transfer of wild-type CD4
+ T lymphocytes into mSOD1/RAG2
 / 
mice did not alter the messenger RNA levels of FoxP3 compared
with wild-type or mSOD1 mice (Fig. 4D). FoxP3 messenger RNA
levels were increased in mSOD1/RAG2
 /  mice receiving mSOD1
CD4
+ T lymphocytes compared with either mSOD1 mice or
mSOD1/RAG2
 /  mice passively transferred with wild-type
CD4 T lymphocytes (Fig. 4D). At 20 weeks of age, the passive
transfer of mSOD1 CD4
+/CD25
+ T lymphocytes into mSOD1/
RAG2
 /  mice further increased FoxP3 messenger RNA levels
compared with mSOD1/RAG2
 /  mice receiving mSOD1 CD4
+
T lymphocytes (Fig. 4D). These results suggest an increase in
the number of FoxP3 expressing cells in the spinal cords of
these mice.
In contrast to the increased message levels of FoxP3, the passive
transfer of wild-type CD4
+ T lymphocytes into mSOD1/RAG2
 / 
mice decreased the messenger RNA levels of Gata-3 compared
with wild-type mice at 20 weeks (Fig. 4E); Gata-3 levels in
mSOD1/RAG2
 /  mice following the passive transfer of
wild-type CD4
+ T lymphocytes were similar to untreated
mSOD1 mice. Although the passive transfer of mSOD1 CD4
+
and mSOD1 CD4
+/CD25
+ T lymphocytes did elevate Gata-3
levels compared with mSOD1 mice, the Gata-3 levels in these
mice did not increase above the assessed levels in wild-type
mice. These results suggest that any contaminating lymphocytes
in the repetitive passive transfers did not contribute to a Th2
response.
As was shown earlier, T-bet messenger RNA was increased in
20-week-old untreated mSOD1 mice compared with wild-type
mice, and the passive transfer of wild-type CD4
+ T lymphocytes
into mSOD1/RAG2
 /  mice did not alter these levels (Fig. 4F).
However, the passive transfer mSOD1 CD4
+ T lymphocytes into
mSOD1/RAG2
 /  mice did decrease the messenger RNA levels of
T-bet compared with wild-type or mSOD1 mice. The passive trans-
fer of mSOD1 CD4
+/CD25
+ T lymphocytes into mSOD1/
RAG2
 /  mice further reduced the T-bet message levels com-
pared with mSOD1/RAG2
 /  mice receiving passive transfers of
mSOD1 CD4
+ T lymphocytes most likely due to the limited numbers
of T-bet expressing lymphocytes in the mSOD1 CD4
+/CD25
+
T lymphocyte pool.
Similar expression patterns to FoxP3 were obtained when the
spinal cords of these animals were assessed for IL-4 messenger
RNA levels. IL-4 messenger RNA levels were increased in the
spinal cords of 20-week-old mSOD1/RAG2
 /  mice receiving
mSOD1 CD4
+ T lymphocytes compared with either mSOD1
mice or mSOD1/RAG2
 /  mice passively transferred with
wild-type CD4
+ T lymphocytes (Fig. 4G). The passive transfer of
mSOD1 CD4
+/CD25
+ T lymphocytes into mSOD1/RAG2
 / 
mice further increased IL-4 messenger RNA levels compared
with mSOD1/RAG2
 /  mice receiving mSOD1 CD4
+ T lympho-
cytes. However, the opposite was detected for the message levels
of INF-g. The messenger RNA levels for IFN-g were decreased in
mSOD1/RAG2
 /  mice receiving mSOD1 CD4
+ T lymphocytes
compared with either mSOD1 mice or mSOD1/RAG2
 /  mice
passively transferred with wild-type CD4
+ T lymphocytes
(Fig. 4H). The passive transfer of mSOD1 CD4
+/CD25
+
T lymphocytes into mSOD1/RAG2
 /  mice further decreased
IFN-g messenger RNA levels compared with mSOD1/RAG2
 / 
mice receiving mSOD1 CD4
+ T lymphocytes. Thus, increased
IL-4, and possibly the reduced toxicity due to the suppressive ef-
fects of the Tregs, may have contributed to the prolonged survival
of mSOD1/RAG2
 /  mice passively transferred with mSOD1
CD4
+ or mSOD1 CD4
+/CD25
+ T lymphocytes.
How the passive transfer of wild-type or mSOD1 CD4
+
T lymphocytes, or mSOD1 Tregs, into mSOD1/RAG2
 /  mice
affected the phenotype of microglia was assessed by measuring
the messenger RNA levels of Ym1 and NOX2 (Fig. 4I and J).
Although passively transferring wild-type CD4
+ T lymphocytes
did not increase the levels of Ym1 in the spinal cord of
Figure 4 Continued
FoxP3 expression levels in the spinal cords of mSOD1/RAG2
 /  mice compared with untreated wild-type (yellow bar) or untreated
mSOD1 mice (blue bar), or compared with mSOD1/RAG2
 /  mice receiving wild-type CD4
+ T lymphocytes (dark blue bar). (E) Gata-3
messenger RNA was suppressed in spinal cords of 20-week-old mSOD1/RAG2
 /  mice receiving wild-type CD4
+ T lymphocytes (dark
blue bar) compared with wild-type mice (yellow bar); similar results were obtained with untreated mSOD1 mice (blue bar). (F) T-bet
messenger RNA was increased in spinal cords of both 20-week-old mSOD1/RAG2
 /  mice receiving wild-type CD4
+ T lymphocytes
(dark blue bar) and untreated mSOD1 mice (blue bar) compared with wild-type mice (yellow bar). (G) The passive transfer of mSOD1
CD4
+ (purple bar) or CD4
+/CD25
+ T lymphocytes (green bar) increased the messenger RNA levels of IL-4 in the spinal cords of
20-week-old mSOD1/RAG2
 /  mice compared with untreated wild-type (yellow bar) or untreated mSOD1 mice (blue bar), or compared
with mSOD1/RAG2
 /  mice receiving wild-type CD4
+ T lymphocytes (dark blue bar). (H) The passive transfer of wild-type CD4
+
(purple bar) increased the messenger RNA levels of IFN-g in the spinal cords of 20-week-old mSOD1/RAG2
 /  mice compared with
untreated wild-type (yellow bar); similar results were obtained with untreated mSOD1 mice (blue bar). However, the passive transfer of
mSOD1 CD4
+ (purple bar) or CD4
+/CD25
+ T lymphocytes (green bar) decreased the messenger RNA levels of IFN-g in 20-week-old
mSOD1/RAG2
 /  mice. (I) The spinal cords of 20-week-old mSOD1/RAG2
 /  mice passively transferred with mSOD1 CD4
+ (purple
bar) or CD4
+/CD25
+ T lymphocytes (green bar) had increased levels of Ym1, a marker of M2 microglia/macrophages, compared with
untreated wild-type (yellow bar) or untreated mSOD1 mice (blue bar), or compared with mSOD1/RAG2
 /  mice receiving wild-type
CD4
+ T lymphocytes (dark blue bar). (J) As a marker of toxic microglia/macrophages, NOX2 messenger RNA was decreased in the spinal
cords of 20-week-old mSOD1/RAG2
 /  mice passively transferred with mSOD1 CD4
+ (purple bar) or CD4
+/CD25
+ T lymphocytes
(green bar) compared with untreated wild-type (yellow bar) or untreated mSOD1 mice (blue bar) or compared with mSOD1/RAG2
 / 
mice receiving wild-type CD4
+ T lymphocytes (dark blue bar). KO = knock out.
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 /  mice at 20 weeks compared with mSOD1
mice, the levels of Ym1 were increased in 20-week
mSOD1/RAG2
 /  mice receiving mSOD1 CD4
+ T lymphocytes
compared with mSOD1 mice or mSOD1/RAG2
 /  mice passively
transferred with wild-type CD4
+ T lymphocytes (Fig. 4I). Passively
transferring mSOD1 Tregs into mSOD1/RAG2
 /  mice further
increased the expression of Ym1 compared with mSOD1/
RAG2
 /  mice receiving mSOD1 CD4
+ T lymphocytes.
The increase in the M2 phenotypic marker Ym1 was associated
with the reduction in the messenger RNA for the M1 marker
NOX2 (Fig. 4J). The passive transfer of wild-type CD4
+ T lympho-
cytes did not alter the levels of NOX2 messenger RNA in the
spinal cord of mSOD1/RAG2
 /  mice at 20 weeks compared
with mSOD1 mice. However, the NOX2 expression levels were
decreased in 20-week mSOD1/RAG2
 /  mice receiving mSOD1
CD4
+ T lymphocytes compared with mSOD1 mice or mSOD1/
RAG2
 /  mice passively transferred with wild-type CD4
+
T lymphocytes (Fig. 4J). In accord with the increased Ym1
messenger RNA levels following the passive transfer mSOD1
Tregs into mSOD1/RAG2
 /  mice, the passive transfer mSOD1
Tregs further decreased the expression of NOX2 compared with
mSOD1/RAG2
 /  mice receiving mSOD1 CD4
+ T lymphocytes.
Thus, not only are the markers of Tregs sustained following the
repetitive passive transfer of mSOD1 T lymphocytes, the pheno-
typic markers of M2 microglia are sustained following the passive
transfer of these lymphocytes.
CD3
+/CD4
+ T lymphocytes are
present in the lumbar spinal cords of
mSOD1 mice
Immunohistochemical examination of lumbar spinal cord sections
from end stage disease mSOD1/RAG2
 /  mice passively trans-
ferred with either wild-type or mSOD1 CD4
+ T lymphocytes
revealed the presence of CD3
+/CD4
+ T lymphocytes; CD3
+
T lymphocytes were not detected in the lumbar spinal cords of
untreated mSOD1/RAG2
 /  mice (Fig. 5A). The T lymphocytes
were mainly clustered in the ventral grey matter, but scattered
T lymphocytes were observed throughout each lumbar spinal
cord section; sections contained 17.1   1.3 CD4
+ T lymphocytes.
The numbers of CD4
+ T lymphocytes were similar between
mSOD1/RAG2
 /  mice passively transferred with either wild-type
or mSOD1 CD4
+ T lymphocytes; however, there were fewer
CD3
+ T lymphocytes in these two groups compared with
mSOD1/RAG2
+/  mice, most likely due to the lack of the previ-
ously documented presence of CD8
+ T lymphocytes (Fig. 5A,
compare panel A2 with panels A3 and A4) (Beers et al. 2008).
Examination of lumbar spinal cord sections from 105-day-old
(stable disease phase) mSOD1/RAG2
 /  mice passively trans-
ferred with stable phase mSOD1 Tregs revealed the presence of
CD3
+/CD4
+ T lymphocytes (Fig. 5A, panel 5). CD3
+ cells were
not detected in lumbar spinal cord sections of mSOD1/RAG2
 / 
mice passively transferred with mSOD1 Tregs at 23 weeks of age,
Figure 5 CD3
+/CD4
+ T lymphocytes were observed in lumbar spinal cord sections of ALS mice. (A) CD3
+ T lymphocytes were not
detected in lumbar spinal cord of untreated mSOD1/RAG2
 /  mice (A1) but were detected in lumbar spinal cords of mSOD1/RAG2
+/ 
mice (A2) and mSOD1/RAG2
 /  mice passively transferred with total wild-type or mSOD1 CD4
+ T lymphocytes (A3 and A4). At
105-days-old, during the stable disease phase, CD4
+ cells were detected in the lumbar spinal cords of mSOD1/RAG2
 /  mice passively
transferred with CD4
+CD25
+ T lymphocytes (A5). (B) CD11b immunohistochemistry demonstrated that morphological microglial acti-
vation was attenuated in untreated end stage disease mSOD1/RAG2
 /  mice (B1) (Beers et al., 2008). Microglial morphology was similar
among end stage disease mSOD1/RAG2
+/  mice (B2) and end stage disease mSOD1/RAG2
 /  mice passively transferred with total
wild-type or mSOD1 CD4
+ T lymphocytes (B3 and B4). Microglia are morphologically activated at 23 weeks of age, rapidly progressing
phase, in mSOD1/RAG2
 /  mice passively transferred with stable phase mSOD1 Tregs (B5). Microglia in the lumbar spinal cords of end
stage disease mSOD1/RAG2
 /  mice passively transferred with stable phase mSOD1 Tregs appeared less morphologically activated (B6).
Scale bars = (A) 100mm; (B) 50mm.
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disease; at these time points, CD4
+CD25
+ cells were detected
in blood, but were FoxP3
-, by ﬂow cytometric analyses (data
not shown). These data suggest that the passively transferred
Tregs are possibly eliminated through apoptosis/necrosis or are
no longer recruited to the spinal cords of these mice (Banerjee
et al., 2008). Thus, since FoxP3 messenger RNA expression
levels were increased at 20 weeks of age in the spinal cords
mSOD1/RAG2
 /  mice passively transferred with mSOD1 Tregs
(Fig. 4D), and since CD3
+ T lymphocytes were not detected in the
spinal cords of 23-week-old mSOD1/RAG2
 /  mice passively
transferred with mSOD1 Tregs (Fig. 5A, panel 5), the elimination
process could have occurred during this 3 week interval.
Using CD11b antibodies, immunohistochemical examination of
lumbar spinal cord sections from end stage disease mSOD1/
RAG2
 /  mice passively transferred with wild-type or mSOD1
CD4
+ T lymphocytes revealed similar microglial morphologies
(Fig. 5B). Furthermore, passive transfer of wild-type or mSOD1
CD4
+ T lymphocytes into mSOD1/RAG2
 /  mice had microglial
morphologies indistinguishable from those observed in
mSOD1/RAG2
+/  mice. Microglia in the lumbar spinal cords of
15-week-old (stable disease phase) or 23-week-old (rapidly pro-
gressing disease phase) mSOD1/RAG2
 /  mice passively trans-
ferred with stable phase mSOD1 Tregs were morphologically
similar to disease staged matched mSOD1/RAG2
 /  mice pas-
sively transferred with either wild-type or mSOD1 CD4
+
T lymphocytes (Fig. 5B); however, microglia in the lumbar spinal
cords of end stage disease mSOD1/RAG2
 /  mice passively
transferred with stable phase mSOD1 Tregs appeared less mor-
phologically activated than end stage disease mSOD1/RAG2
 / 
mice passively transferred with either wild-type or mSOD1 CD4
+
T lymphocytes, suggesting a morphologically incomplete reversion
to a state observed in untreated mSOD1/RAG2
 /  mice (Fig. 5B).
CD11b staining of lumbar spinal cord sections from end stage
disease mSOD1/RAG2
 /  mice conﬁrmed an attenuated micro-
glial activated morphology (Beers et al., 2008).
IL-4 is co-expressed with FoxP3
in mouse regulatory T lypmphocytes
Since IL-4 messenger RNA was increased in the lumbar spinal
cords of mSOD1 mice during the stable disease phase, and since
the passive transfer of mSOD1 CD4
+/CD25
+ T lymphocytes
extended the stable phase and prolonged survival of recipient
mSOD1/RAG2
 /  mice, we asked whether the selected
mSOD1 CD4
+/CD25
+ T lymphocytes used for the passive trans-
fers, and for the subsequent in vitro studies, co-expressed IL-4.
We isolated CD4
+/CD25
+ T lymphocytes from lymph nodes and
spleens from 108-day-old stable phase mSOD1 mice and
age-matched wild-type mice in an identical manner as used for
the passive transfer studies, and then analysed 50000 lympho-
cytes from both mSOD1 and wild-type mice by ﬂow cytometry
using antibodies to CD4, CD25, FoxP3 and IL-4; ﬂow cytometric
gates were established based on unstained cells. These analyses
revealed that 480% of the CD4
+/CD25
+T lymphocytes were
FoxP3
+ in both mSOD1 and wild-type T lymphocyte pools.
Furthermore, these analyses demonstrated that IL-4 was
co-expressed with FoxP3 in both mSOD1 and wild-type CD4
+/
CD25
+ T lymphocytes; 95% of the CD4
+/CD25
+/FoxP3
+
lymphocytes from mSOD1 and wild-type mice were IL-4
+
(Fig. 6A and B). In mSOD1 mice, CD4
+/CD25
+/FoxP3
 /IL-4
+,
which may contain Th2 lymphocytes, represented 6% of the total
selected T lymphocytes, whereas in wild-type mice, these
T lymphocytes represented 3% of the total selected T lympho-
cytes. More importantly, re-gating the ﬂow cytometric results
showed that there were 57% more FoxP3
+/IL-4
high T lympho-
cytes in mSOD1 CD4
+/CD25
+ T lymphocytes than with
wild-type CD4
+/CD25
+ T lymphocytes; re-gating these results
also demonstrated that there were few FoxP3
-/IL-4
highT lympho-
cytes in the selected pools of T lymphocytes from mSOD1 and
wild-type mice (Fig. 6C and D).
To eliminate possible alterations in IL-4 expression in the pool of
CD4
+/CD25
+ T lymphocytes due to the prolonged isolation times
used to select these lymphocytes, we also prepared fresh cell sus-
pensions from lymph nodes dissected from 105-day-old stable
phase mSOD1 and wild-type mice, and immediately subjected
these cells to ﬂow cytometric analyses using antibodies to CD3,
CD4, CD25, FoxP3 and IL-4. These analyses again revealed that
IL-4 was co-expressed by CD3
+/CD4
+/CD25
+/FoxP3
+
T lymphocytes in the lymph nodes of mSOD1 and wild-type
mice (Fig. 6E and F). In these lymph nodes, 3% of the total
mSOD1 cells were CD3
+/CD4
+/CD25
+/FoxP3
+/IL-4
+, whereas
2% of the wild-type lymph node cells were CD3
+/CD4
+/CD25
+/
FoxP3
+/IL-4
+; 80% of the mSOD1 FoxP3
+ T lymphocytes were
IL-4
+ and 53% of the wild-type FoxP3
+ T lymphocytes
were IL-4
+. Again, re-gating these results showed that there
were 200% more CD3
+/CD4
+/CD25
+/FoxP3
+/IL-4
high
T lymphocytes in mSOD1 mice lymph nodes than wild-type
lymph nodes (Fig. 6G and H). Thus, these results suggest that
the extended stable disease phase and the enhanced survival of
mSOD1/RAG2
 /  mice receiving repetitive passive transfers of
mSOD1 CD4
+/CD25
+ T lymphocytes may be due to the
increased numbers of CD4
+/CD25
+ T lymphocytes from stable
phase mSOD1 mice and because these T lymphocytes have an
increased number of FoxP3
+/IL-4
high T lymphocytes; there were
consistently 2–3 times more mSOD1 Tregs isolated from mSOD1
mice than similarly isolated wild-type Tregs from age- and genetic
background-matched wild-type mice. Furthermore, in mice on a
C57Bl/6 genetic background, it appears that Tregs co-express
FoxP3 and IL-4 on a single cell level.
Tregs suppress the toxic and enhance
the protective attributes of microglia
Since IL-4 was shown to be co-expressed in mSOD1 Tregs and to
determine whether IL-4 released by mSOD1 and wild-type mice
Tregs is a potential mechanism for how T lymphocytes may modu-
late the protective versus toxic responses of microglia, freshly iso-
lated adult 100-day-old wild-type or mSOD1 Teffs and Tregs were
co-cultured with primary adult 130-day-old microglia obtained
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+/CD25
+ T lymphocytes. (A and B) CD4
+/CD25
+ T lymphocytes were isolated in an
identical manner from the spleens and lymph nodes of mSOD1 and wild-type (WT) mice as used ﬂow the repetitive passive transfer
studies. Using antibodies to CD4, CD25, FoxP3 and IL-4, ﬂow cytometric analyses demonstrated on the single cell level the co-expression
IL-4 and FoxP3 in CD4
+/CD25
+ T lymphocytes in mSOD1 and wild-type mice. (C and D) Moving the gates up, there are more IL-4
+ high/
FoxP3
+ T lymphocytes in mSOD1 CD4
+/CD25
+ T lymphocytes than with wild-type CD4
+/CD25
+ T lymphocytes. (E and F) To eliminate
possible IL-4 expression alterations in the pool of CD
+/CD25
+ T lymphocytes, we also prepared fresh lymph node cell suspensions from
mSOD1 and wild-type mice. The cells were immediately subjected to ﬂow cytometric analyses using antibodies to CD3, CD4, CD25,
FoxP3 and IL-4. Again, IL-4 was found to be co-expressed with FoxP3 on a single cell level in CD3
+/CD4
+/CD25
+ T lymphocytes. (G and H)
Moving the gates up, there are more IL-4
+ high/FoxP3
+ T lymphocytes in mSOD1 CD3
+/CD4
+/CD25
+ T lymphocytes than with
wild-type CD3
+/CD4
+/CD25
+ T lymphocytes. The numbers in each quadrant in each of the eight ﬂow cytometry panels reﬂect the
percentages of the total number of live cells in that quadrant.
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obtained during the stable disease phase in mSOD1 mice.
Culturing wild-type microglia with either wild-type Teffs or
wild-type Tregs did not alter the NOX2 messenger RNA levels
assayed by quantitative reverse transcriptase polymerase chain
reaction; the NOX2 levels expressed in wild-type microglia were
at baseline. When cultured alone, mSOD1 microglia expressed
693% more NOX2 messenger RNA than primary wild-type micro-
glia (data not shown). When co-cultured with Teffs, mSOD1
microglia expressed more NOX2 messenger RNA than wild-type
microglia co-cultured with wild-type Teffs (Fig. 7A). When
co-cultured with Tregs, NOX2 expression in mSOD1 microglia
was decreased to levels detected in wild-type microglia
co-cultured with wild-type Tregs; T lymphocytes expressed
undetectable levels of NOX2 (data not shown).
Because IL-4 and IL-10 messenger RNA levels were elevated
during the stable disease phase in mSOD1 mice (Fig. 2B and C),
we investigated whether these cytokines were responsible for the
suppression of NOX2 microglial messenger RNA expression. IL-4
protein in the supernatants of microglia co-cultured with either
Teffs or Tregs was assayed by enzyme-linked immunosorbent
assay; in the absence of T lymphocytes, microglia did not express
detectable levels of IL-4 messenger RNA (Zhao et al., 2006).
Teffs co-cultured with adult primary mSOD1 or wild-type
microglia produced equivalent amounts of IL-4 protein (Fig. 7B).
The supernatants of wild-type microglia co-cultured with
wild-type Tregs contained increased levels of IL-4. When
mSOD1 microglia were co-cultured with mSOD1 Tregs, the super-
natants contained more IL-4. To demonstrate whether IL-4 from
Tregs contributed to the suppressed microglial NOX2 messenger
RNA expression, an anti-IL-4 blocking antibody was added to the
co-cultures. The anti-IL-4 antibody reversed the suppressive
effects of IL-4 induced by the Tregs and the NOX2 messenger
RNA levels rose to levels detected in co-cultures with Teffs
(Fig. 7C).
Since Tregs are known to produce IL-10, we next asked
whether IL-10 released by Tregs plays a role in suppressing micro-
glial toxic functions (Sakaguchi et al., 2008). IL-10 messenger
RNA levels were at baseline when wild-type microglia were
co-cultured with wild-type Teffs; wild-type microglia expressed
minimal IL-10 messenger RNA (data not shown). When mSOD1
microglia were co-cultured with mSOD1 Teffs, the levels of IL-10
messenger RNA were not increased from that detected in the
wild-type microglia/wild-type Teffs co-cultures (Fig. 7D). When
wild-type microglia were co-cultured with wild-type Tregs, the
IL-10 messenger RNA level was increased and were further
increased when mSOD1 microglia were co-cultured with mSOD1
Tregs; wild-type and mSOD1 Teffs expressed equivalent levels of
IL-10 messenger RNA (Fig. 7E). Conversely, stable phase mSOD1
Tregs expressed increased IL-10 messenger RNA levels compared
with age-matched wild-type Tregs. Anti-IL-10 blocking antibodies
did not block the NOX2 messenger RNA suppressive effects of
Tregs in co-cultures of microglia and T lymphocytes as previously
described using anti-IL-4 antibodies (Fig. 7F), suggesting that the
protective effects of microglia can be predominantly modulated by
Tregs through their release of IL-4.
Regulatory T lypmphocytes are
decreased in the blood of patients with
amyotrophic lateral sclerosis with
rapidly progressing disease
Since Tregs were increased during the stable disease phase in ALS
mice, and since the passive transfer of endogenous mSOD1 CD4
+
T lymphocytes isolated during this phase lengthened disease
duration by extending the stable disease phase, thus prolonging
survival, ﬂow cytometric analyses were used to determine whether
Tregs numbers in the blood of patients with ALS were also
associated with slower disease progression. Freshly drawn blood
samples from 54 patients with the clinical diagnosis of deﬁnite or
probable sporadic ALS and 33 volunteer subjects were analysed
for their percentages of CD3
+, CD4
+, CD8
+ or CD4
+CD25
+
Tregs. The percentage of CD3
+, CD4
+, CD8
+ or Tregs in the
blood was not different between patients with ALS and controls
(data not shown). However, when the patients with ALS were
separated into slowly versus rapidly progressing patients based
on the rate of disease progression using the Appel ALS score,
there were 27% fewer CD4
+ T lymphocytes in the rapidly pro-
gressing patients with ALS (51.5 Appel ALS points/month) com-
pared with the slowly progressing patients with ALS (51.5 Appel
ALS points/month); slowly progressing patients with ALS had the
same percentage of CD4
+ T lymphocytes as controls (50000 cells
were counted; in the volunteers, there were 6755 CD4
+ T
lymphocytes, and in the slow and fast progressing patients there
were 6395 and 4650 CD4
+ T lymphocytes, respectively) (Fig. 8A).
There were 31% fewer CD4
+CD25
+ Tregs in rapidly progressing
patients than slowly progressing patients; there was no difference
in the percentage of CD4
+CD25
+ Tregs in slowly progressing
patients with ALS compared with volunteer subjects (in the
same number of cells, there were 422 CD4
+/CD25
+ T lympho-
cytes in the control volunteers, and 413 and 287 CD4
+/CD25
+
T lymphocytes in the slow versus fast progressing patients with
ALS, respectively) (Fig. 8B). Most importantly, the percentage of
CD4
+CD25
+ Tregs in the blood of patients with ALS were in-
versely correlated with the rate of disease progression; the greater
the number of CD4
+CD25
+ Tregs the slower the rate of disease
progression (Fig. 8C). These results suggest an association
between the greater the percentage of Tregs in the blood with
the rate at which a patient with ALS progresses.
Discussion
This study demonstrates an association between the numbers of
Tregs in the blood and lymph nodes, and FoxP3 messenger RNA
in the spinal cord, with the stable disease progression phase in
mSOD1 mice. Speciﬁcally, CD4
+CD25
+ and CD25
+FoxP3
+
Tregs were increased during the disease stable phase, and then
decreased with accelerating disease burden. Without ex vivo
expansion, the passive transfer of T lymphocytes, and more spe-
ciﬁcally Tregs, obtained from donor mSOD1 animals during the
stable phase directly extended the stable disease progression phase
and prolonged survival of recipient mSOD1/RAG2
 /  mice. The
Endogenous regulatory T lymphocytes ameliorate ALS disease Brain 2011: 134; 1293–1314 | 1307Figure 7 Tregs suppress toxic microglial responses through a mechanism involving the upregulation of IL-4. Wild-type (WT) and mSOD1
primary microglia (mc) were harvested from 130-day-old mice. Wild-type and mSOD1 T lymphocytes were obtained from 100-day-old
mice. (A) Co-culturing mSOD1 Teffs with mSOD1 microglia increased NOX2 messenger RNA expression compared with wild-type
microglia co-cultured with wild-type Teffs (*P = 0.021). Co-culturing wild-type microglia with wild-type Tregs did not change the ex-
pression of NOX2 compared with wild-type microglia co-cultured with wild-type Teffs (
#P50.05). mSOD1 Tregs obtained from stable
disease phase mSOD1 mice reduced the NOX2 messenger RNA expression from mSOD1 microglia to levels detected in wild-type
microglia/Tregs co-cultures. mSOD1 microglia/Tregs expressed less NOX2 messenger RNA than mSOD1 microglia/Teffs (**P = 0.022).
(B) IL-4 levels in the supernatant from wild-type Teffs/microglia were not different than the supernatant IL-4 levels from mSOD1 Teffs /
microglia co-cultures (
#P50.05). Co-culturing stable phase mSOD1 Tregs with mSOD1 microglia increased the amount of IL-4 in the
supernatant compared with wild-type microglia/Tregs co-cultures (*P = 0.007). (C) Although anti-IL-4 blocking antibodies (Ab) did not
alter the expression levels on NOX2 messenger RNA in mSOD1 microglia/Teffs co-cultures, they increased the NOX2 messenger RNA
expression in mSOD1 microglia/Tregs compared with untreated mSOD1 microglia/Tregs co-cultures (*P = 0.0008) and were not different
from mSOD1 microglia/Teffs co-cultures treated with anti-IL-4 antibodies (
##P50.05), suggesting that the suppressive effects of mSOD1
Tregs was mediated through an IL-4 mechanism (Zhao et al., 2006). (D) IL-10 messenger RNA was increased in mSOD1 microglia/Tregs
co-cultures compared with wild-type microglia/Tregs (*P = 0.032) or mSOD1 microglia/Teffs co-cultures (**P = 0.004). (E) Both
wild-type Tregs and mSOD1 Tregs had increased IL-10 messenger RNA levels compared with wild-type Teffs (*P50.001 and
**P = 0.008) or mSOD1 Teffs (
&P = 0.0004 and
&&P = 0.008). (F) Again, mSOD1 Tregs reduced the level of NOX2 messenger RNA
expression in mSOD1 microglia/Tregs co-cultures compared with mSOD1 microglia/Teffs (*P50.001), but the anti-IL-10 blocking
antibodies did not reverse NOX2 messenger RNA expression in mSOD1 microglia/Tregs compared with untreated mSOD1 microglia/
Tregs co-cultures (
#P50.05), suggesting that the suppressive effects of mSOD1 Tregs did not involve IL-10.
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be attributable to the release of IL-4 and maintenance of M2
microglia; the neuroprotection may also be attributable to the
release of glial-derived neurotrophic factor and brain-derived
neurotrophic factor, neurotrophic factors previously shown to
directly protect neurons (Serpe et al., 2005; Reynolds et al.,
2007; Tiemessen et al., 2007). Furthermore, ﬂow cytometric ana-
lyses conﬁrmed that the CD4
+CD25
+ T lymphocytes isolated
from stable phase mSOD1 mice and used for the repetitive passive
transfer studies indeed co-expressed FoxP3 and IL-4 on a single
cell level; Gata-3 messenger RNA levels suggest that T lympho-
cytes with a Th2 phenotype may have a limited pathogenic role in
the lumbar spinal cords of mSOD1 mice, although they may have
a greater role in the peripheral compartment. Thus, as disease
progresses, there is an operational transformation from a support-
ive Tregs/M2 effect to an injurious Th1/M1 response, indicating
that lymphocytes obtained at early time points are immunocom-
petent and actively contribute to neuroprotection through their
release of IL-4 and neurotrophic factors, and interactions with
microglia; T lymphocytes are necessary in part by rendering resi-
dent microglia capable of neural maintenance and repair (Fig. 9)
(Kipnis and Schwartz, 2005). More importantly, these observations
were extended into the ALS patient population where decreased
numbers of Tregs in the blood of patients with ALS were
correlated with faster disease progression.
The data presented in this report indicate that wild-type CD4
+
T lymphocytes are neuroprotective because the repetitive passive
transfer of these lymphocytes into mSOD1/RAG2
 /  mice
restored the stable disease phases and survival times of these
mice. Furthermore, the passive transfer of mSOD1 CD4
+ T
lymphocytes provided additional beneﬁcial protection because
they contained greater numbers of CD4
+/CD25
+/FoxP3
+
lymphocytes that co-expressed higher levels of IL-4. Moreover,
the passive transfer of a lymphocyte population enriched for
CD4
+/CD25
+ lymphocytes, which increased the numbers of
FoxP3
+ and IL-4
high T lymphocytes, further extended the stable
disease phase and prolonged survival. Therefore, these data sug-
gest that the higher the content of IL-4 expressing Tregs, the
greater the neuroprotection in mSOD1 mice.
The elevation of Tregs, M2 cells and neurotrophic factors in the
spinal cords of mSOD1 mice at disease onset suggests a protect-
ive/repair response; the early increased levels of glial-derived
neurotrophic factor and FoxP3 messenger RNAs mirrors the upre-
gulation of glial-derived neurotrophic factor following the adoptive
transfer of ex vivo activated Tregs into a mouse model of
Parkinson’s disease (Reynolds et al., 2007). The increase of
Tregs in the spinal cords of stable phase mSOD1 mice is paralleled
by the increase in IL-4 and IL-10 messenger RNAs, probably
released by the Tregs, resulting in the induction of M2 microglia.
Thus, these initial responses led to slowing and stabilization of the
disease pathoprogression. Although IL-4 messenger RNA levels are
reduced from earlier time points, they are still elevated in mSOD1
mice at end stage disease compared with wild-type mice. We
previously demonstrated that CD4
+ T lymphocytes are present
at end stage disease in mSOD1 mice; we rigorously counted
lymphocytes in lumbar spinal cord sections and provided evidence
that not only are CD4
+ T lymphocytes increasing but also are
Figure 8 Decreased numbers of Tregs in blood are inversely
correlated with a rapid rate of progression in patients with ALS.
(A) Using the Appel ALS (AALS) scoring system, there were 27%
fewer CD4
+ T lymphocytes in rapidly progressing patients with
ALS (a disease progression rate of 51.5 Appel ALS points/
month) compared with slowly progressing patients with ALS (a
disease progression rate of 51.5 Appel ALS points/month;
P = 0.02). Rapidly progressing patients had fewer CD4
+ T
lymphocytes than volunteer subjects (P = 0.009). (B) There were
31% fewer CD4
+CD25
+ Tregs in rapidly progressing patients
(51.5 Appel ALS points/month) compared with slowly pro-
gressing patients (51.5 Appel ALS points/month) (P = 0.02);
volunteer control subjects had 47% more CD4
+CD25
+ Tregs
than rapidly progressing patients (P = 0.003). (C) There was a
linear inverse correlation between the number of CD4
+CD25
+
Tregs in the blood of patients with ALS and rate of disease
progression (P = 0.03).
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+ lymphocytes (Beers et al., 2008). These CD4
+ T lympho-
cytes are probably a mixture of Th1 and Th2 Teffs. Th2 lympho-
cytes are possibly recruited to sites of injury in mSOD1 mice
providing the limited IL-4 messenger RNA level. Furthermore,
the Ym1 messenger RNA data coincide well with the IL-4 data.
Thus, M2 cells are not completely eliminated, but their numbers,
or possibly their phenotypic abilities to suppress inﬂammation, are
reduced to levels that are less effective in the presence of a pro-
inﬂammatory milieu that occurs during the rapidly progressing dis-
ease phase, and at end stage disease.
Because Gata-3 was restored to wild-type levels in mSOD1/
RAG2
 /  mice receiving repetitive passive transfers of mSOD1
CD4
+ or CD4
+/CD25
+ T lymphocytes, these results may be
interpreted to suggest that there is an inﬁltration of T lymphocytes
with a Th2 phenotype into the lumbar spinal cords of these mice
due to the presence of CD4
+/CD25
+/FoxP3
-/IL-4
+ lymphocytes
in the pool of selected mSOD1 CD4
+ or CD4
+/CD25
+ T lympho-
cytes, but the results more likely suggest that due to these treat-
ments, the Gata-3 levels were not suppressed in other CNS cells
such as microglia and astrocytes, just as it is not suppressed in
untreated 16-week-old mSOD1 mice, and because the Gata-3
messenger RNA levels did not rise above untreated wild-type
mice levels; the passive transfer of wild-type CD4
+ T lymphocytes
into mSOD1/RAG2
 /  mice did not restore the Gata-3 messen-
ger RNA levels, or increase the messenger RNA level of FoxP3 and
IL-4 in the lumbar spinal cords of these mice (Wallach et al.,
Figure 9 In ALS mice, there is a transformation from protective stabilizing effects of Tregs and M2 microglia to an injurious Teffs and M1
microglial response. The presence of Tregs shifts the balance of microglia responses from cytotoxicity to increased neuroprotection.
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CD4
+ or CD4
+/CD25
+ T lymphocytes did increase the messen-
ger RNA levels of both FoxP3 and IL-4 above wild-type levels in
lumbar spinal cords of these 20-week-old treated mSOD1/
RAG2
 /  mice. Thus, if the IL-4 was produced solely by Th2
lymphocytes present in the selected pool of CD4
+/CD25
+
T lymphocytes, then the IL-4 messenger RNA expression in the
spinal cords of these mice would have been greater in the mSOD1
CD4
+ T lymphocytes than in the CD4
+/CD25
+ T lymphocytes.
Nevertheless, the small numbers of CD4
+/CD25
+/FoxP3
-/IL-4
+
Th2 lymphocytes in the pool of selected and repetitively passively
transferred mSOD1 CD4
+/CD25
+ T lymphocytes may have con-
tributed in a limited manner to the extended stable disease phase
and prolonged survival of treated mSOD1/RAG2
 /  mice; however,
this interpretation does not negate the enhanced neuroprotective
role of IL-4 and the greater contribution provided by the aug-
mented numbers of the CD4
+/CD25
+/FoxP3
+/IL-4
+ T lympho-
cytes in this pool. Furthermore, this interpretation is not intended
to reﬂect the inﬂammatory response that occurs in the cervical
spinal cords of mSOD1 mice. Earlier studies reported that
mSOD1 mice ﬁrst developed hindlimb tremors, then progressive
hindlimb weakness with rapidly deteriorating gaits, which eventu-
ally culminated in paralysis of one or both hindlimbs; forelimb
weakness occurred later if at all and in some mice, disease pro-
gressed so rapidly that they were sacriﬁced before any signs of
forelimb involvement were observed (Gurney et al., 1994; Wong
et al., 1995; Bruijn et al., 1997). Because of these observations,
we recently evaluated whether there were differential protective
versus injurious inﬂammatory responses in the cervical and lumbar
spinal cords that could explain the temporally distinct clinical dis-
ease courses between the limbs of these mice (Beers et al., 2010).
In that report, we detected a 2- to 3-fold increase in Gata-3 mes-
senger RNA levels in the cervical regions of 14- and 16-week-old
mSOD1 mice compared with their respective lumbar regions; this
level was also increased compared with the Gata-3 levels detected
in the cervical regions of wild-type mice. Therefore, under patho-
logical stress induced by the overexpression of mSOD1, there are
distinct regional and temporal differences in the neuroinﬂamma-
tory responses that occur in the spinal cords of mSOD1 mice,
possibly due to the heterogeneity of the microglial and inﬁltrating
T lymphocyte responses between the cervical and lumbar regions.
At 18 weeks, there is a transformation from a neuroprotective
Tregs/Th2 and M2 response to an injurious Th1/M1 response
leading to the acceleration of disease. Indeed, the temporal pat-
terns for CD28, CD80, CD86 and chemokine (C–C motif) ligand 2
(CCL2) messenger RNAs suggest a switch in the adaptive/innate
immune responses. This transformation is represented by increased
microglial messenger RNA expression levels of NOX2, IL-1b and
by IL-12, as well as by the increased Th1 levels of T-bet and
IFN-g. The transformation from protection to toxicity may coincide
with the expression of IL-6; IL-6 completely inhibits the generation
of FoxP3
+ Tregs (Bettelli et al., 2006). Since IL-6 can be produced
by activated CNS astrocytes, in addition to Th1 lymphocytes, and
since astrocytosis is known to occur during disease progression,
astrocytes may be one cellular source of IL-6 that may contribute
to the inhibition of Tregs in mSOD1 mice (Van Wagoner and
Benveniste, 1999; Alexianu et al., 2001; Beers et al., 2008,
2010). Thus, IL-6 may be a key factor that transforms Tregs/
Th2 and M2 responses into Th1/M1 responses. Interestingly,
IL-6 and transforming growth factor-b messenger RNAs are
expressed between 16 and 20 weeks, which may indicate the
presence of pro-inﬂammatory Th17 cells, but IL-17 expression,
the product of a Th17 cell response, was not detected; multiple
IL-17 primer sets were used and ampliﬁed IL-17 in experimental
autoimmune encephalomyelitis mice. These results indicate a
dialogue among motoneurons, microglia, astrocytes, and the
accompanying inﬁltrating lymphocytes (Appel et al., 2010).
Understanding this cellular dialogue may reveal how to manipulate
the immune system to extend the stable phase and inhibit the
induction of the rapidly accelerating disease phase.
The passive transfers of 90–95% pure stable phase mSOD1
Tregs into recipient mSOD1/RAG2
 /  mice resulted in the exten-
sion of the stable phase by 3.5 weeks (88% increase) and
prolonged mean survival times by 18 days compared with
age-matched wild-type CD4
+ T lymphocytes, possibly due to
the increased Tregs production of IL-4 and/or trophic factors; dis-
ease onset was not different between the groups but the passive
transfer of mSOD1 Tregs into younger mSOD1/RAG2
 /  mice
may delay disease onset (Banerjee et al., 2008). It should be
emphasized, and contrasted with a previous report, that the
isolated Tregs were not ex vivo expanded (Banerjee et al.,
2008). The passively transferred mSOD1 CD4
+ or wild-type
T lymphocytes remained predominantly CD4
+ T lymphocytes;
few CD8
+ T lymphocytes were identiﬁed by ﬂow cytometry in
blood collected from mice prior to euthanasia and in spinal cord
sections stained immunohistochemically with anti-CD8 antibodies.
mSOD1/RAG2
 /  mice passively transferred with mSOD1 CD4
+
T lymphocytes harvested from rapidly progressing 20-week-old
mSOD1 mice did not extend duration times or prolong survival
compared with mice passively transferred with wild-type CD4
+
T lymphocytes, again suggesting the immunosuppressive effects
of the increased numbers of Tregs obtained from stable phase
mSOD1 mice. mSOD1/RAG2
 /  mice passively transferred with
Teffs resulted in multi-organ damage or autoimmunity due to the
lack of compensatory Tregs (Sakaguchi et al., 2010). Thus, the
increased numbers of mSOD1 Tregs harvested from donor
mSOD1 mice during the stable phase enhanced the M2 microglia
neuroprotection. Although this study indicates that functional
Tregs are present early, the Tregs are inhibited beginning at 16
weeks, with the functional consequences of this process not
manifested until 18 weeks, at which time the animal enters into
the rapidly progressing phase; the timing of these events coincides
with when FoxP3 ﬂuorescence/cell levels in the blood and lymph
nodes are reduced to approximately wild-type levels. Furthermore,
mSOD1 CD4
+ lymphocytes isolated from the early stable phase
mSOD1 mice results in a more protective T lymphocyte response
when compared with the response induced by wild-type
T lymphocytes, possibly due to enhanced numbers of Tregs sus-
taining IL-4 levels and an M2 microglial response. However, an
alternate explanation for the enhanced protective potentials of
these early disease phase isolated mSOD1 T lymphocytes may
be due to an early ‘education’ process occurring in mSOD1 mice
that was not available to the wild-type T lymphocytes in the
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RAG2
 /  mice.
In light of these results, the presence of Tregs was assessed in
the blood of patients with sporadic ALS. The percentage of Tregs
was decreased in rapidly progressing patients with sporadic ALS
compared with slowly progressing patients with sporadic ALS.
Compared to control populations, the percentage of Tregs in
slowly progressing patients was unchanged suggesting that the
normal default status of Tregs may be to protect against
Th1-mediated toxicity. It is also possible that the inability to docu-
ment an increase in Tregs in slowly progressing patients with ALS,
as was documented during the stable disease phase in mSOD1
mice, may be due to the fact that patients are not diagnosed
and available for blood testing at symptom onset or even prior
to the appearance of symptoms. When we analysed our results
as previously reported, separating the patients based on ALS
functional rating scale revised (ALSFRS-R) 424 and ALS func-
tional rating scale revised (ALSFRS-R) 424, representing lower
and higher disease severity, respectively, the number of Tregs
still inversely correlated with disease severity (Mantovani et al.,
2009). The contradictory results obtained between the two reports
are not entirely evident. However, the discrepancy may lie in the
details for the analysis methods. Their analyses may have been
based upon each patient serving as their own control, whereas
ours were based on the means of each control group, thus
reducing the potential variability.
Since IL-4 and IL-10 messenger RNAs were elevated in the
spinal cords of stable phase mSOD1 mice, the suppressive effects
of Tregs isolated from stable phase mSOD1 mice were assayed in
primary adult microglia co-cultures. In contrast to age-matched
Teffs, Tregs efﬁciently suppressed microglial NOX2 messenger
RNA expression. More importantly, the addition of anti-IL-4 anti-
bodies reversed the suppressive effects of Tregs on microglial
NOX2 messenger RNA expression. We previously demonstrated
that IL-4 suppressed superoxide and nitric oxide release, and atte-
nuated the LPS-induced microglia-mediated motoneuron injury
using primary microglial/motoneuron co-cultures; the extent of
nitric oxide suppression correlated directly with the extent of
motoneuron survival (Zhao et al., 2006). Using a viral vector ex-
pression of IL-4, Kiyota et al. (2010) showed that IL-4 reduced
microgliosis and improved spatial learning in a mouse model of
Alzheimer’s disease. Furthermore, another recent study demon-
strated a critical role for T lymphocyte derived IL-4 in the regula-
tion of cognitive functions; depletion of T lymphocytes or IL-4
skewed meningeal myeloid cells towards a pro-inﬂammatory
phenotype and cognitive deﬁcits, and passive transfer of T
lymphocytes reversed the cognitive impairments and attenuated
the pro-inﬂammatory response (Derecki et al., 2010). These cu-
mulative data suggest that T lymphocytes, and more speciﬁcally
Tregs, provide an immunomodulatory IL-4 signal that protects
motoneurons against M1 microglial-mediated neurotoxicity and
that anti-inﬂammatory cytokine signalling may be a potential
alternative target for ameliorating the devastating effects of
neurodegenerative diseases.
Since the default state of microglia is an M2 phenotype that is
responsible for the maintenance of CNS homeostasis and preven-
tion of neuronal damage, our data suggest that Tregs assist
microglia in maintaining an M2 phenotype (Appel et al., 2010).
The ability of Tregs to modulate microglial inﬂammation, cell func-
tion and speciﬁc enzymatic activities provides novel tools to
manipulate ongoing microglial inﬂammatory responses; it is clear
that there is cross-talk between the immune system and brain, and
this dialogue merits our full attention (Lucin and Wyss-Coray,
2009; Appel et al., 2010). In addition, we established that
endogenous T lymphocytes, and more speciﬁcally Tregs, are
increased at early slowly progressing stages, suggesting a beneﬁ-
cial immunomodulatory response early in disease. This immuno-
modulatory beneﬁt was demonstrated by the passive transfer of
wild-type or mSOD1CD4
+ T lymphocytes, without ex vivo acti-
vation, into ALS mice lacking functional T lymphocytes and
lengthened disease duration and prolonged survival. The passive
transfer of endogenous Tregs from early disease stage mSOD1
mice into ALS mice, again without ex vivo activation, was further
shown to have substantially greater immunomodulatory beneﬁt
compared with ALS mice receiving wild-type or mSOD1 CD4
+ T
lymphocytes. The secretion of IL-4 by mSOD1 Tregs, which can
directly suppress the toxic properties of microglia, represents a
potential mechanism for this enhanced life expectancy; ﬂow
cytometric analyses determined that CD4
+/CD25
+/FoxP3
+ T
lymphocytes co-expressed IL-4 on a single cell level. These
unique observations found in ALS mice were extended into the
ALS patient population where patients with more rapidly progress-
ing disease had decreased numbers of Tregs; the numbers of Tregs
were inversely correlated with disease progression rates. Thus,
these studies provided compelling evidence that the presence of
Tregs are neuroprotective and support a rationale for Tregs im-
munotherapy in patients with ALS. However, immunotherapeutic
interventions must begin early in the pathogenic process since
immune dysfunction occurs at later disease stages. Furthermore,
these data suggest that increasing the levels of Tregs in patients
with ALS might slow the rate of disease progression and stabilize
patients for longer periods of time than other currently available
therapies, thus enhancing their quality of life.
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